AC Immune (ACIU) announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board, CAB. Prof. Mummery leads the cognitive disorders service at the UK’s National Hospital for Neurology and Neurosurgery, where she has practiced as a consultant neurologist since 2004.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune’s ACI-24.060 Study: A Potential Game-Changer in Alzheimer’s Treatment
- AC Immune’s Innovative PET Tracer Study: A Potential Game-Changer for Neurodegenerative Diagnostics
- AC Immune’s Innovative PET Radioligand Study: A Potential Game-Changer in Neurodegenerative Diagnostics
- AC Immune SA: Pioneering Innovations in Neurodegenerative Disease Treatment and Diagnostics
- AC Immune announces publication of preclinical data on ACI-19626